Astrazeneca Pharma Key Ratios
NSE: ASTRAZEN | BSE: 506820
₹6,139.00
As on 18-Nov-2026 14:19IST
Market cap
₹15,628 Cr
Revenue (TTM)
₹2,602 Cr
P/E Ratio
87.9
P/B Ratio
17.8
Div. Yield
0.6 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | 6.78 | 30.41 | 29.70 | 31.62 | 27.13 |
| EBIT | 106.41 | 24.25 | -15.90 | 4.70 | 22.14 |
| Net Profit | 91.21 | 25.29 | -18.93 | 3.27 | 21.70 |
| EPS | 64.33 | 14.96 | -10.76 | 5.17 | 20.31 |
| Book Value | -- | -- | 13.51 | 13.91 | 13.77 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Mar-26 | Mar-25 |
| EBIT-Margin
| 11.94 | 11.85 | 8.85 | 10.26 | 12.47 |
| Net Margin
| 8.96 | 8.80 | 6.74 | 8.14 | 6.59 |
| Return on equity
| 21.23 | 18.92 | 21.49 | 23.02 | 15.73 |
| Return on Capital
| 28.83 | 25.67 | -- | 31.24 | 21.29 |
| Return on Assets
| 9.89 | 9.14 | 9.34 | 8.90 | 7.43 |
| Debt to Equity (x)
| -- | -- | 0.00 | 0.00 | 0.00 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astrazeneca Pharma
|
--
|
31.24
|
21.29
|
33.94
|
24.49
|
|
Peer Median
|
--
|
21.28
|
21.76
|
21.89
|
--
|
ROE
21.49
Higher than Peers by 6.57
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astrazeneca Pharma
|
21.49
|
23.02
|
15.73
|
24.95
|
18.13
|
|
Peer Median
|
14.92
|
18.29
|
17.93
|
16.42
|
--
|
ROA
9.34
Lower than Peers by 0.51
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astrazeneca Pharma
|
9.34
|
8.90
|
7.43
|
13.35
|
9.37
|
|
Peer Median
|
9.85
|
9.88
|
12.81
|
12.32
|
--
|
EBIT Margin
8.85
Lower than Peers by 8.83
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astrazeneca Pharma
|
8.85
|
10.26
|
12.47
|
13.08
|
14.84
|
|
Peer Median
|
17.68
|
18.36
|
18.93
|
21.05
|
--
|
Net Margin
6.74
Lower than Peers by 7.03
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astrazeneca Pharma
|
6.74
|
8.14
|
6.59
|
12.14
|
9.65
|
|
Peer Median
|
13.77
|
13.31
|
14.94
|
15.51
|
--
|
Cash Profit Margin
--
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astrazeneca Pharma
|
--
|
9.47
|
9.04
|
13.55
|
11.47
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
29.70
Higher than Peers by 17.05
Year on year growth in net sales
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astrazeneca Pharma
|
29.70
|
32.59
|
32.48
|
29.17
|
24.50
|
|
Peer Median
|
12.65
|
16.05
|
10.90
|
13.44
|
--
|
EBIT Growth
-15.90
Lower than Peers by 39.29
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astrazeneca Pharma
|
-15.90
|
9.10
|
26.23
|
13.87
|
115.02
|
|
Peer Median
|
23.39
|
20.72
|
15.01
|
23.50
|
--
|
Net Profit Growth
-18.93
Lower than Peers by 41.71
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astrazeneca Pharma
|
-18.93
|
62.02
|
-28.34
|
62.66
|
61.19
|
|
Peer Median
|
22.78
|
20.10
|
14.80
|
30.12
|
--
|
EPS Growth
-10.76
Lower than Peers by 32.16
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astrazeneca Pharma
|
-10.76
|
62.02
|
-28.34
|
62.66
|
61.19
|
|
Peer Median
|
21.40
|
19.29
|
14.27
|
29.02
|
--
|
Book Value Growth
--
--
Year on year growth in book value per share
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astrazeneca Pharma
|
--
|
13.51
|
7.70
|
20.90
|
15.05
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astrazeneca Pharma
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.00
|
0.05
|
0.06
|
0.03
|
--
|
Current Ratio
1.63
Lower than Peers by 0.40
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astrazeneca Pharma
|
1.63
|
1.68
|
1.70
|
2.23
|
1.93
|
|
Peer Median
|
2.03
|
1.90
|
1.90
|
2.23
|
--
|
Quick Ratio
0.76
Lower than Peers by 0.78
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astrazeneca Pharma
|
0.76
|
0.75
|
1.10
|
1.74
|
1.54
|
|
Peer Median
|
1.54
|
1.40
|
1.46
|
1.59
|
--
|
Interest Coverage
36.15
Higher than Peers by 14.38
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astrazeneca Pharma
|
36.15
|
57.17
|
108.10
|
183.95
|
213.86
|
|
Peer Median
|
21.76
|
19.02
|
24.96
|
45.29
|
--
|
Operating Efficiency
Debtors to sales
10.95
Lower than Peers by 10.30
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astrazeneca Pharma
|
10.95
|
9.39
|
10.77
|
11.82
|
10.72
|
|
Peer Median
|
21.25
|
20.44
|
21.77
|
20.10
|
--
|
Asset Turnover
1.37
Higher than Peers by 0.65
Sales / Average Total Assets
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astrazeneca Pharma
|
1.37
|
1.08
|
1.11
|
1.08
|
0.95
|
|
Peer Median
|
0.72
|
0.74
|
0.76
|
0.81
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astrazeneca Pharma
|
--
|
31.88
|
35.81
|
36.53
|
35.03
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astrazeneca Pharma
|
--
|
126.03
|
82.25
|
58.60
|
59.85
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astrazeneca Pharma
|
--
|
163.79
|
124.39
|
131.27
|
214.92
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astrazeneca Pharma
|
--
|
-5.88
|
-6.33
|
-36.14
|
-120.04
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
87.93
Higher than Peers by 55.16
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astrazeneca Pharma
|
87.93
|
103.45
|
185.90
|
82.35
|
81.76
|
|
Peer Median
|
32.76
|
32.76
|
26.81
|
39.85
|
--
|
Price / Book Value
17.78
Higher than Peers by 13.47
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astrazeneca Pharma
|
17.78
|
22.39
|
28.19
|
18.77
|
13.85
|
|
Peer Median
|
4.31
|
4.38
|
4.65
|
6.11
|
--
|
Dividend Yield
0.58
Higher than Peers by 0.14
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astrazeneca Pharma
|
0.58
|
0.46
|
0.37
|
0.45
|
0.49
|
|
Peer Median
|
0.44
|
0.48
|
0.61
|
0.37
|
--
|
EV/EBITDA
52.69
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astrazeneca Pharma
|
52.69
|
65.23
|
71.21
|
58.36
|
39.84
|
|
Peer Median
|
--
|
25.44
|
27.02
|
34.57
|
--
|
Market Cap
15,628
Lower than Peers by 1,822
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astrazeneca Pharma
|
15,628
|
19,399
|
21,516
|
13,301
|
8,118
|
|
Peer Median
|
17,450
|
17,111
|
20,914
|
25,297
|
--
|